ALDR - Alder BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.06
+0.05 (+0.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close11.01
Open11.10
Bid10.85 x 1100
Ask11.39 x 3000
Day's Range10.92 - 11.23
52 Week Range9.44 - 20.87
Volume414,473
Avg. Volume1,084,017
Market Cap923.552M
Beta (3Y Monthly)3.25
PE Ratio (TTM)N/A
EPS (TTM)-4.81
Earnings DateJul 27, 2017 - Jul 28, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
  • GlobeNewswire2 days ago

    Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 50,000 shares of Alder’s common stock to a new employee under Alder’s 2018 Inducement Award Plan, effective May 21, 2019. The stock option will vest with respect to 25% of the shares underlying the option one year after the employee’s employment start date and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36 month period following the one year anniversary of the employee’s employment start date, subject to the employee’s continued service to Alder through each relevant vesting date.  The option has a ten year term and an exercise price of $11.35 per share, which is equal to the closing price of Alder’s common stock on May 21, 2019.

  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of ALDR earnings conference call or presentation 25-Feb-19 10:00pm GMT

    Q4 2018 Alder Biopharmaceuticals Inc Earnings Call

  • GlobeNewswire12 days ago

    Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences

    BOTHELL, Wash., May 14, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • GlobeNewswire18 days ago

    Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced a new analysis of patient-reported outcomes data from the PROMISE-2 Phase 3 clinical trial of eptinezumab for the prevention of chronic migraine. Eptinezumab is an investigational monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) administered by quarterly infusion for migraine prevention.

  • Here’s What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)
    Insider Monkey19 days ago

    Here’s What Hedge Funds Think About Alder Biopharmaceuticals Inc (ALDR)

    With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Alder Biopharmaceuticals Inc (NASDAQ:ALDR). Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was in […]

  • Markit19 days ago

    See what the IHS Markit Score report has to say about Alder Biopharmaceuticals Inc.

    Alder Biopharmaceuticals Inc NASDAQ NMS:ALDRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ALDR are favorable, with net inflows of $1.71 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
    Zacks20 days ago

    Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

    Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

  • GlobeNewswire20 days ago

    Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new efficacy data highlighting consistency of early migraine prevention benefit across four clinical trials with eptinezumab. Eptinezumab is an investigational monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) and is administered by quarterly infusion for migraine prevention.

  • Bob Azelby awaits approval of Alder’s migraine drug
    American City Business Journals23 days ago

    Bob Azelby awaits approval of Alder’s migraine drug

    In a significant milestone for Alder, the U.S. Food and Drug Administration agreed on April 22 to review the biologics license application for the company’s flagship migraine drug, the company discovered and developed over the last decade. FDA approval could come as early as the first quarter of 2020.

  • Alder BioPharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Call Transcript
    Motley Fool23 days ago

    Alder BioPharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Call Transcript

    ALDR earnings call for the period ending March 31, 2019.

  • Associated Press24 days ago

    Alder BioPharmaceuticals: 1Q Earnings Snapshot

    The Bothell, Washington-based company said it had a loss of $1.63 per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results

    BOTHELL, Wash., April 26, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the.

  • Analysts point to potential Biogen M&A options after Alzheimer's failure
    American City Business Journalslast month

    Analysts point to potential Biogen M&A options after Alzheimer's failure

    Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.

  • Why This Migraine-Focused Biotech Stock Could Be The Next Takeover
    Investor's Business Dailylast month

    Why This Migraine-Focused Biotech Stock Could Be The Next Takeover

    Alder Biopharmaceuticals could be an acquisition target, an analyst said Tuesday after the Food and Drug Administration accepted its application for a migraine-prevention treatment.

  • Benzingalast month

    The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...

  • GlobeNewswirelast month

    Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting

    BOTHELL, Wash., April 23, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the.

  • GlobeNewswirelast month

    U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for eptinezumab. Eptinezumab is an investigational monoclonal antibody (mAb), administered intravenously, for migraine prevention targeting the calcitonin gene-related peptide (CGRP) and is Alder’s lead commercial candidate. If the FDA grants approval of eptinezumab, Alder anticipates a Q1 2020 commercial launch.

  • GlobeNewswire2 months ago

    Alder BioPharmaceuticals® Appoints Nadia Dac as Chief Commercial Officer

    Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Nadia Dac as chief commercial officer (CCO), effective April 8, 2019.  She will report to Bob Azelby, Alder’s president and chief executive officer. “Nadia brings an impressive degree of relevant commercial experience with prior leadership roles in marketing and sales at global biopharmaceutical companies, including a track record of successfully launching multiple novel neurology products in competitive markets,” said Bob Azelby. “We are excited to have Nadia join the Alder team.

  • GlobeNewswire2 months ago

    Alder BioPharmaceuticals® to Present at the 18th Annual Needham Healthcare Conference

    BOTHELL, Wash., April 02, 2019 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment.

  • Alder Biopharmaceuticals CEO: Spreading migraine awareness
    CNBC Videos2 months ago

    Alder Biopharmaceuticals CEO: Spreading migraine awareness

    Jim Cramer chats with Alder Biopharmaceuticals CEO Robert Azelby to find out what the company is doing to address chronic migraine.